Incidence of early adverse events surrounding direct current cardioversion of persistent atrial fibrillation. A cohort study of practices

Therapie

Volumn 62, Issue 1, 2007, Pages 45-48

  Guédon Moreau, Laurence ^a,e   Gayet, Jean Louis ^b   Galinier, Michel ^c   Frances, Yves ^b   Lardoux, Hervé ^d   Libersa, Christian ^a  

^a Department of Pharmacology University ^*  (France)

^b Hospital and University Centre   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d University Hospital   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Adverse events; Atrial fibrillation; Cardioversion

Indexed keywords

AGED; ARTICLE; BRADYCARDIA; CARDIOVERSION; CLINICAL PRACTICE; COHORT ANALYSIS; DIRECT CURRENT; FEMALE; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART VENTRICLE ARRHYTHMIA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT PROLONGATION; BLEEDING; HEART ARRHYTHMIA; LONG QT SYNDROME; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AGED; ARRHYTHMIA; ATRIAL FIBRILLATION; BRADYCARDIA; COHORT STUDIES; ELECTRIC COUNTERSHOCK; FEMALE; HEMORRHAGE; HUMANS; LONG QT SYNDROME; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34249722271     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2007009     Document Type: Article

References (12)

1. Lown B, Amarasingham R, Neuman J. New method for terminating cardiac arrhythmias.Use of synchronized capacitor discharge. JAMA 1986; 256: 621-627
2. Mead GE, Flapan AD, Elder AT. Electrical cardioversion for atrial fibrillation and flutter. Cochrane Database Syst Rev 2002; (1): CD002903
3. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology Committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2001; 22: 1852-1923
4. Gentile F, Elhendy A, Khandheria BK, et al. Safety of electrical cardioversion in patients with atrial fibrillation. Mayo Clin Proc 2002; 77: 897-904
5. Stellbrink C, Nixdorff U, Hofmann T, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004; 109: 997-1003
6. Klein AL, Murray RD, Grimm RA, et al. Bleeding complications in patients with atrial fibrillation undergoing cardioversion randomized to transesophageal echocardiographically guided and conventional anticoagulation therapies. Am J Cardiol 2003; 92: 161-165
7. Tieleman RG, Gosselink AT, Crijns HJ, et al. Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol 1997; 79: 53-57
8. Weinberg DM, Mancini J. Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol 1989; 63: 745-746
9. Arnold AZ, Mick MJ, Mazurek RP, et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992; 19: 851-855
10. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356: 1789-1794
11. Van Gelder I, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840
12. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833